BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Juno Therapeutics, Inc. (“Juno” or the “Company”) (NASDAQ: JUNO) concerning the Company and its officers’ possible violations of federal securities laws.
Juno is a biopharmaceutical company that engages in the development of anti-cancer therapies. The Company specializes in pharmaceutical technologies that are designed to genetically engineer T cells to recognize and kill cancer cells.
On July 7, 2016, post-market, Juno disclosed that three patients had passed away during a clinical trial for the Company's chemotherapy drug JCAR015.
On this news, Juno's share price fell significantly in value, dropping almost 32%, or $13.01 per share, to close at $27.81 per share on July 8, 2016.
If you purchased Juno securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.